bioihbjkbjnl/mcl2 huggingface dataset:
Comparing Nifedipine and Enalapril in Medical Resources Used in the Postpartum Period
Condition: Hypertension in Pregnancy; Preeclampsia Severe; Gestational Hypertension; Postpartum Preeclampsia; Postpartum
MeSH terms: Pre-Eclampsia; Hypertension, Pregnancy-Induced; Hypertension
Intervention: NIFEdipine ER; Enalapril
Intervention description: Postpartum women with high blood pressure will be randomized to receive nifedipine extended release 30mg daily as their starting antihypertensive.; Postpartum women with high blood pressure will be randomized to receive enalapril 10 mg daily as their starting antihypertensive.
Intervention MeSH terms: Enalapril; Nifedipine
Phase: Phase 4
Study type: Interventional
Primary purpose: Treatment
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: None (Open Label)
Enrollment: 94.0
Sex: Female
Minimum age: 18 Years
Healthy volunteers: Accepts Healthy Volunteers

Summary:

      This study evaluates whether nifedipine or enalapril is better at decreasing the amount of
      medical resources used in the postpartum period by women who have high blood pressure in
      pregnancy and the postpartum period. Half of participants will receive enalapril while the
      other half will receive enalapril. We will compare the two groups in the amount of medical
      resources used which we are defining as prolonged hospitalizations, unscheduled medical
      visits and/or hospital readmissions in the postpartum period.
    

Eligibility criteria:

        Inclusion Criteria:

          -  diagnosis of any hypertensive disorder of pregnancy/postpartum period or chronic
             hypertension

          -  provider wanting to initiate antihypertensive in the postpartum period

          -  the patient is not currently on >1 antihypertensive

          -  plans to receive postpartum care at the hospital or affiliated clinic

        Exclusion Criteria:

          -  sustained pulse <60 or >120 BPM over four hours

          -  allergy to any of the antihypertensives

          -  creatinine greater than or equal to 1.5

          -  strict contraindication to any of the antihypertensives

          -  history of failed treatment with any of the antihypertensives
The Effect of Sugammadex Versus Neostigmine on Postoperative Pulmonary Complications
Condition: Postoperative Complications; Neuromuscular Blockade
MeSH terms: Postoperative Complications
Intervention: Sugammadex; Neostigmine
Intervention description: At the end of the surgical procedure at a depth of neuromuscular blockade after the reappearance of T2 on the train-of-four, Sugammadex will be dosed once at 2 mg/kg through an intravenous line with brisk flow; At the end of surgical procedure at a depth of neuromuscular blockade after the reappearance of T2 on the train-of-four, Neostigmine will be dosed once at 0.07 mg/kg to a maximum of 5 mg through an intravenous line with brisk flow. Glycopyrrolate will be administered with Neostigmine at a dose between 0.1 to 0.2 mg of Glycopyrrolate per 1.0 mg of Neostigmine administered.
Intervention MeSH terms: Neostigmine
Phase: Phase 4
Study type: Interventional
Primary purpose: Prevention
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Enrollment: 200.0
Sex: All
Minimum age: 70 Years
Healthy volunteers: Accepts Healthy Volunteers
Keywords: Sugammadex; Neuromuscular Blockade

Summary:

      Substantial respiratory morbidity has been associated with postoperative residual paralysis,
      which is fairly common after general anesthesia involving a neuromuscular blocking agent.
      Common practice in United States is to reverse neuromuscular blockade with neostigmine at the
      end of surgery. A new drug with evidence of more complete neuromuscular reversal has been
      developed, sugammadex. The objective of this study is to determine if a strategy of
      rocuronium neuromuscular reversal with sugammadex will reduce the proportion of subjects with
      any postoperative pulmonary complication, compared to neostigmine.
    

Eligibility criteria:

        Inclusion Criteria:

          -  Age ≥ 70 years

          -  Elective surgery Monday through Friday in the South Operating Rooms of Oregon Health
             and Science University (OHSU)

          -  Planned general endotracheal anesthesia

          -  Expected surgical duration ≥ 3 hours

        Exclusion Criteria:

          -  Prisoners

          -  An inability to consent for surgery or anesthesia

          -  Surgery for which neuromuscular blockade is contraindicated (e.g. neurosurgical,
             orthopedic, and head and neck surgery in which nerve monitoring will be employed)

          -  A known neuromuscular disorder

          -  Stage 4 chronic kidney disease or worse (estimated glomerular filtration rate < 30
             ml/min)

          -  Liver Disease

          -  An allergies to Sugammadex, Rocuronium, Neostigmine, or Glycopyrrolate

          -  Patients taking Toremifene
Prophylaxis of Periprosthetic Joint Infections With Calcium Sulfate Beads in Patients With Non-modifiable Risk Factors.
Condition: Infection
MeSH terms: Infections; Communicable Diseases
Intervention: Antibiotic local prophylaxis with medicated calcium sulfate beads; Classical parenteral antibiotic prophylaxis
Intervention description: Antibiotic prophylaxis in patients with non-modifiable risk factors for periprosthetic joint infection; Antibiotic prophylaxis in patients with non-modifiable risk factors for periprosthetic joint infection
Intervention MeSH terms: Anti-Bacterial Agents; Antibiotics, Antitubercular; Calcium
Phase: Phase 4
Study type: Interventional
Primary purpose: Prevention
Allocation: Randomized
Intervention model: Parallel Assignment
Intervention model description: Randomised controlled trial. Study participants are randomly assigned to one of two groups: the experimental group receiving the Calcium sulfate beds with antibiotics and a comparison group (control) which receives a conventional prophylactic therapy.
Masking: Single (Participant)
Masking description: No participant will know during the study in which group will be assigned.
Enrollment: 87.0
Sex: All
Minimum age: 60 Years
Healthy volunteers: No
Keywords: Periprosthetic Joint Infection; Prophylaxis; Joint Replacement; Calcium Sulfate Beads

Summary:

      To demonstrate the prophylactic effect of calcium sulfate beads loaded with antibiotic in
      patients with non-modifiable risk factors that will undergo a hip or knee joint replacement,
      comparing with a control group.

      To know the economic cost generated in antibiotic prophylaxis with calcium sulfate beads in
      patients undergoing hip or knee joint replacement with non-modifiable risk factors.
    

Eligibility criteria:

        Inclusion Criteria:

          -  patients with fracture or osteoarthrosis of the hip or knee that require treatment by
             joint replacement.

          -  patients who have any of the Non-Modifiable Risk Factors prior to surgery or during
             transoperative period.

          -  Patients entitled to the ISSEMyM (Instituto de Seguridad Social del Estado de Mexico y
             Municipios)

        Exclusion Criteria:

          -  Patients that lose their validity of institutional rights and do not follow up

          -  Patients who die during the study due to other causes not related to the orthopedic
             procedure.

          -  Patients who do not have any of the risk factors for periprosthetic infection

          -  Patients allergic to vancomycin or ceftriaxone.
Morphine Versus Methadone for Opiate Exposed Infants With Neonatal Abstinence Syndrome
Condition: Neonatal Abstinence Syndrome
MeSH terms: Neonatal Abstinence Syndrome; Syndrome
Intervention: Morphine; Methadone
Intervention description: Morphine wean protocol as described in arm description; Methadone wean protocol as described in arm description
Intervention MeSH terms: Morphine; Methadone
Phase: Phase 4
Study type: Interventional
Primary purpose: Treatment
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: None (Open Label)
Enrollment: 61.0
Sex: All
Minimum age: 0 Hours
Maximum age: 12 Hours
Healthy volunteers: No

Summary:

      This study investigates the use of methadone versus morphine wean for the treatment of
      neonatal abstinence syndrome for infants exposed to opioids in utero. Half of infants who
      require pharmacotherapy for NAS will receive a methadone wean, and half will receive a
      morphine wean. Length of hospital stay, length of treatment and parent satisfaction will be
      studied.
    

Eligibility criteria:

        Inclusion criteria:

          -  Born at University of New Mexico Hospital

          -  Greater than 34 weeks gestation

          -  Primary in-utero drug exposure was opioids other than buprenorphine

          -  Maternal or infant urine drug screen positive for methadone and/or opioids on
             admission

        Exclusion criteria:

          -  Born prior to 34 weeks

          -  Neonatal intensive care unit admission

          -  Serious medical comorbidities

          -  Primary substance exposure in-utero was buprenorphine, or was not opioids
Sufentanil Infusion vs Sufentanil Bolus
Condition: Anesthesia
Intervention: Sufentanil Infusion; Sufentanil Bolus
Intervention description: Intra-operative sufentanil infusion; Intra-operative sufentanil bolus
Intervention MeSH terms: Sufentanil; Dsuvia
Phase: Phase 4
Study type: Interventional
Primary purpose: Treatment
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Single (Participant)
Enrollment: 64.0
Sex: All
Minimum age: 19 Years
Maximum age: 80 Years
Healthy volunteers: Accepts Healthy Volunteers

Summary:

      Randomized single blind controlled clinical trial to test the benefit of sufentanil infusion
      over bolus dosing to reduce time to extubation and reduced length of ICU stay.
    

Eligibility criteria:

        Inclusion Criteria:

          -  Scheduled non-emergency cardiac surgical patients including those with planned
             procedures of CABG, AVR, and combined CABG and AVR

          -  19 to 80 years old

          -  Planned pre-operative anesthesia screening visit and/or preoperative surgical clinic
             visit.

          -  Inpatient subject that is scheduled (greater than 24hrs in advance) for a
             non-emergency cardiac surgical case

        Exclusion Criteria:

          -  Sufentanil allergy

          -  EF less than or equal to 30%

          -  Moderate or severe right ventricular dysfunction,

          -  Moderate pulmonary dysfunction, to include patients with at home 02 and/or daily
             bronchodilator therapy.

          -  End Stage Renal Disease on Dialysis

          -  Chronic Kidney Disease with GFR <30

          -  Sternotomy Re-do

          -  Emergency surgery

          -  Greater than 4 units of RBCs or FFP combined

          -  Mechanical circulatory support post-operatively such as ECMO, IABP, Impella

          -  Not eligible for rapid wean extubation protocol

          -  Requires infusion of sedative medication required during ICU admission

          -  Greater than or equal to 15 minute ICU hold within PACU
Perioperative Intravenous Lidocaine Infusion for Patients Undergoing Laparoscopic and Open Pancreatectomies
Condition: Pancreatectomy
Intervention: Lidocaine; Placebo D5W
Intervention MeSH terms: Lidocaine
Phase: Phase 4
Study type: Interventional
Primary purpose: Treatment
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Enrollment: 48.0
Sex: All
Minimum age: 18 Years
Maximum age: 80 Years
Healthy volunteers: No

Summary:

      The purpose of this study is to evaluate if a lidocaine infusion will provide benefit to
      pancreatectomy patients in regards to analgesia and return of bowel function.
    

Eligibility criteria:

        Inclusion Criteria:

          -  All adult patients undergoing elective open or laparoscopic total pancreatectomies and
             pancreatoduodenectomies (i.e., Whipple procedure), and participating in the Enhanced
             Recovery Protocol (ERP) at Mayo Clinic in Florida.

          -  Age 18 - 80 years old

          -  American Society of Anesthesiologist (ASA) class I - III

          -  BMI < 40

          -  Ability to understand and read English

        Exclusion Criteria:

          -  Not able or willing to sign consent

          -  Intolerance or allergy to opioids, NSAIDS, acetaminophen, or amide-type local
             anesthetics (i.e., lidocaine).

          -  History of epilepsy or currently receiving treatment for seizures

          -  Severe hepatic insufficiency (Child-Pugh Score C)

          -  Renal insufficiency (creatinine clearance less than 30 mL/minute)

          -  Advance heart failure (NY Heart failure stage 3 or greater; Ejection function <30%)

          -  Cardiac arrhythmias: 2nd and 3rd degree heart block, sick sinus syndrome, symptomatic
             bradyarrhythmias, Wolff-Parkinson-White (WPW) syndrome, or Stokes-Adams syndrome; Left
             bundle branch block or bifascicular block; Not to exclude patients the following
             conditions unless clinical circumstance dictate: Atrial fibrillation or atrial
             fluTter; Presence of Implantable Cardioverter Defibrillator (ICD), or pacemakers

          -  Patients on anti-arrhythmic therapy (i.e., digoxin, amiodarone, flecainide, lidocaine,
             sotalol, etc.). Not to exclude patients on beta blockers (i.e., metoprolol, atenolol,
             etc.) unless clinical circumstance dictate

          -  Patients with active psychiatric disorders or cognitive dysfunction

          -  Pregnancy or lactating

          -  Enucleation, central, and distal pancreatectomy

          -  Opioid tolerance (defined as consumption of greater than 30 mg of oxycodone per day)
the Analgesic Duration of Dexmedetomidine Compared to Dexamethasone as Adjuncts to Single Shot Interscalene Block
Condition: Opioid Use, Unspecified
Intervention: Ropivacaine; Dexmedetomidine; Dexamethasone
Intervention description: local anesthetics adjuvants. Ropivacaine 0.5% 20ml. pre-operative single shot interscalene nerve block under ultrasound guidance and peripheral nerve stimulation in patients undergoing ambulatory shoulder surgery; local anesthetics adjuvants. 75mcg of dexmedetomidine. pre-operative single shot interscalene nerve block under ultrasound guidance and peripheral nerve stimulation in patients undergoing ambulatory shoulder surgery; local anesthetics adjuvants. 4mg dexamethasone. pre-operative single shot interscalene nerve block under ultrasound guidance and peripheral nerve stimulation in patients undergoing ambulatory shoulder surgery
Intervention MeSH terms: Dexamethasone; Dexmedetomidine; Ropivacaine; Anesthetics
Phase: Phase 4
Study type: Interventional
Primary purpose: Treatment
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Double (Participant, Care Provider)
Enrollment: 105.0
Sex: All
Minimum age: 18 Years
Maximum age: 60 Years
Healthy volunteers: No
Keywords: post operative pain, Dexmedetomidine, Regional anesthesia

Summary:

      The purpose of the study is to determine if perineural dexmedetomidine can provide increased
      prolongation of analgesia when compared to perineural dexamethasone in patients receiving
      regional block for shoulder surgery. If so, dexmedetomidine may serve as a superior adjunct
      to peripheral nerve blocks in a rapidly evolving, ambulatory-centered surgical setting.
    

Eligibility criteria:

        Inclusion Criteria :

          -  ASA 1 and 2

          -  18-60 years old

          -  Patients scheduled for ambulatory arthroscopic or open surgery

        Exclusion Criteria:

          -  ASA 3 and 4

          -  Pre-existing pain disorder

          -  Regular consumption of chronic pain medication

          -  Anatomical abnormalities of upper extremity

          -  Known allergy or hypersensitivity to Ropivacaine or other amide local anesthetics

          -  Known allergy to dexmedetomidine

          -  Coagulopathy

          -  Uncontrolled Diabetes
Self-Administered Nitrous Oxide (SANO) During Transrectal Prostate Biopsy to Reduce Patient Anxiety and Pain
Condition: Prostate Disease; Malignancy; Benign Prostatic Hyperplasia; Prostate Cancer; Prostate Adenocarcinoma; Anxiety and Fear; Pain
MeSH terms: Prostatic Neoplasms; Prostatic Hyperplasia; Prostatic Diseases; Hyperplasia; Anxiety Disorders
Intervention: Self-Administered Nitrous Oxide; Oxygen
Intervention description: Nitrous oxide administered at concentrations of mild sedation (20-45%) for the duration of prostate biopsy.; Oxygen will be administered at 10 Liters/min for the duration of prostate biopsy.
Intervention MeSH terms: Nitrous Oxide
Phase: Phase 4
Study type: Interventional
Primary purpose: Supportive Care
Allocation: Randomized
Intervention model: Parallel Assignment
Intervention model description: Subjects will be randomized 1:1 to either SANO (treatment) or oxygen (placebo control) after completion of baseline assessment. The results of the randomization will not be disclosed to patients as part of the study (patient-blinded).
Masking: Double (Participant, Care Provider)
Masking description: The operating urologist and study participant will be blinded to group assignment for the duration of the study.
Enrollment: 143.0
Sex: Male
Minimum age: 18 Years
Maximum age: 85 Years
Healthy volunteers: Accepts Healthy Volunteers
Keywords: prostate biopsy; nitrous oxide; prostate cancer; ambulatory; patient experience of care

Summary:

      Transrectal prostate biopsy is a commonly performed ambulatory procedure for diagnosing
      prostate cancer. Prostate biopsy are associated with pain or anxiety. Nitrous oxide (or
      laughing gas) is a well-known inhaled anesthetic which is frequently used in dental offices
      and for pediatric procedures to alleviate a patient's anxiety and pain. This study seeks to
      determine whether administration of nitrous oxide at the time of prostate biopsy will improve
      a patient's experience of care.
    

Eligibility criteria:

        Inclusion Criteria:

          -  Biological male

          -  Aged 18 to 85 years

          -  Scheduled for clinically-indicated prostate needle biopsy

          -  Suitable for nitrous oxide/oxygen with willingness to be randomized to inhaled SANO or
             inhaled oxygen during the procedure

          -  Access to an email and computer

        Exclusion Criteria:

          -  Perioral facial hair impeding good mask seal

          -  Learning disabilities and/or inability to cognitively complete survey questions

          -  Taken a pre-procedure benzodiazepine or narcotic.

          -  Has any of the following medical conditions:

               1. Inner ear, bariatric or eye surgery within the last 2 weeks,

               2. Current emphysematous blebs,

               3. Severe B-12 deficiency.

               4. Bleomycin chemotherapy within the past year.

               5. Class III or higher heart failure.

               6. Undergoing novel therapy for prostate cancer
Improving Sleep Quality in Heart Failure
Condition: Sleep Disturbance; Heart Failure
MeSH terms: Dyssomnias; Parasomnias; Heart Failure
Intervention: Zolpidem Tartrate; Placebo oral capsule
Intervention description: Zolpidem tartrate 5 mg capsule one per night taken for 7 nights; Placebo capsule one per night taken for 7 nights
Intervention MeSH terms: Zolpidem
Phase: Phase 4
Study type: Interventional
Primary purpose: Treatment
Allocation: Randomized
Intervention model: Parallel Assignment
Intervention model description: Single-site, randomized, parallel, placebo controlled, double blind study
Masking: Double (Participant, Investigator)
Enrollment: 5.0
Sex: All
Minimum age: 21 Years
Maximum age: 79 Years
Healthy volunteers: No

Summary:

      Poor sleep quality is common in patients with heart failure. The limited available evidence
      intimates that improving sleep quality in patients with heart failure may improve morbidity
      and quality of life in this patient population. However, there is a paucity of evidence
      assessing the use of effective pharmacologic therapies in heart failure. The
      nonbenzodiazepine, GABA receptor agonist, zolpidem, has been found to have considerable
      benefits over traditional benzodiazepines as a soporific medication. The investigators
      hypothesize that zolpidem will safely improve sleep quality in patients with heart failure.
    

Eligibility criteria:

        Inclusion Criteria:

          -  Age 21-79 years old

          -  HFrEF, EF ≤ 45% (by echocardiography)

          -  NYHA functional class I to III

          -  Able to give written consent

          -  On goal-directed medical therapy for HF, with stable dosing of HF medications for 2
             weeks prior to enrollment

          -  No hospitalizations for HF within the past month

          -  Positive response to experiencing any of the following sleep-related symptoms at least
             once a week:

          -  Difficulty falling asleep

          -  Waking up during the night and having difficulty getting back to sleep

          -  Waking up too early in the morning and being unable to get back to sleep.

        Exclusion Criteria:

          -  Use of sedative-hypnotics, anxiolytic, or benzodiazepines within the previous 2 weeks

          -  Current treatment with other sedating medications such as opioids

          -  On therapy for pharmacological therapy for depression

          -  History of alcohol/drug dependence

          -  History of liver disease, HIV, or severe COPD

          -  On Thorazine

          -  Current use of ketoconazole

          -  Current use of tricyclic antidepressants

          -  Current use of macrolide antibiotics

          -  Current use of anticonvulsant medications

          -  Pregnancy. A urine pregnancy test will be performed to exclude pregnancy in potential
             subjects.